Loading clinical trials...
Loading clinical trials...
Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration
Conditions
Interventions
CNTO 2476
iTrack Model 275 micro catheter
Locations
2
United States
Arcadia, California, United States
Philadelphia, Pennsylvania, United States
Start Date
October 21, 2010
Primary Completion Date
March 31, 2015
Completion Date
May 31, 2017
Last Updated
August 8, 2017
NCT05913063
NCT06990269
NCT06970665
NCT07160179
NCT06557460
NCT05562947
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions